183 related articles for article (PubMed ID: 38539538)
41. Parotid Salivary Duct Carcinoma With a Prominent Squamous Component: Immunohistochemical Profile, Diagnostic Pitfalls, and Therapeutic Implications.
Hardy N; Thompson J; Mehra R; Drachenberg CB; Hatten K; Papadimitriou JC
Int J Surg Pathol; 2021 Oct; 29(7):726-730. PubMed ID: 33683973
[TBL] [Abstract][Full Text] [Related]
42. A 20-Year Review of 75 Cases of Salivary Duct Carcinoma.
Gilbert MR; Sharma A; Schmitt NC; Johnson JT; Ferris RL; Duvvuri U; Kim S
JAMA Otolaryngol Head Neck Surg; 2016 May; 142(5):489-95. PubMed ID: 26939990
[TBL] [Abstract][Full Text] [Related]
43. Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma.
Masubuchi T; Tada Y; Maruya S; Osamura Y; Kamata SE; Miura K; Fushimi C; Takahashi H; Kawakita D; Kishimoto S; Nagao T
Int J Clin Oncol; 2015 Feb; 20(1):35-44. PubMed ID: 24553861
[TBL] [Abstract][Full Text] [Related]
44. Metastatic Salivary Duct Carcinoma with ERBB2 Amplification and Sequential Response to Ado-Trastuzumab Emtansine and Neratinib: A Case Report.
Asper N; Roth KS; Hany TF; Salzberg SP; Tinguely M; Kadvany Y; Trojan A
Case Rep Oncol; 2023; 16(1):1500-1507. PubMed ID: 38033416
[TBL] [Abstract][Full Text] [Related]
45. The Role of the EZH2 and H3K27me3 Expression as a Predictor of Clinical Outcomes in Salivary Duct Carcinoma Patients: A Large-Series Study With Emphasis on the Relevance to the Combined Androgen Blockade and HER2-Targeted Therapy.
Saigusa N; Hirai H; Tada Y; Kawakita D; Nakaguro M; Tsukahara K; Kano S; Ozawa H; Kondo T; Okami K; Togashi T; Sato Y; Urano M; Kajiwara M; Shimura T; Fushimi C; Shimizu A; Okamoto I; Okada T; Suzuki T; Imanishi Y; Watanabe Y; Sakai A; Ebisumoto K; Sato Y; Honma Y; Yamazaki K; Ueki Y; Hanazawa T; Saito Y; Takahashi H; Ando M; Kohsaka S; Matsuki T; Nagao T
Front Oncol; 2021; 11():779882. PubMed ID: 35186711
[TBL] [Abstract][Full Text] [Related]
46. Case report: Salivary duct carcinoma in a patient with a germline
Desai N; Racila E; Fujioka N; Gupta A; Antonarakis ES
Front Oncol; 2024; 14():1372382. PubMed ID: 38651154
[TBL] [Abstract][Full Text] [Related]
47. Salivary duct carcinoma: A clinopathological report of 11 cases.
Huang X; Hao J; Chen S; Deng R
Oncol Lett; 2015 Jul; 10(1):337-341. PubMed ID: 26171026
[TBL] [Abstract][Full Text] [Related]
48. A phase 2 multicenter study of docetaxel-PM and trastuzumab-pkrb combination therapy in recurrent or metastatic salivary gland carcinomas.
Lee J; Park S; Jung HA; Lee SH; Seo S; Kim SB; Kim JW; Lee KW; Kang EJ; Kim JW; Choi YJ; Shim BY; An HJ; Park LC; Shin SH; Kim JJ; Oh SY; Kim MK; Ahn MJ
Cancer; 2023 Oct; 129(19):2966-2974. PubMed ID: 37246414
[TBL] [Abstract][Full Text] [Related]
49. Salivary duct carcinoma: Updates in histology, cytology, molecular biology, and treatment.
Nakaguro M; Tada Y; Faquin WC; Sadow PM; Wirth LJ; Nagao T
Cancer Cytopathol; 2020 Oct; 128(10):693-703. PubMed ID: 32421944
[TBL] [Abstract][Full Text] [Related]
50. Intensity Modulated Radiotherapy (IMRT) With Carbon Ion Boost in the Multimodal Treatment of Salivary Duct Carcinoma.
Adeberg S; Windisch P; Ehret F; Baur M; Akbaba S; Held T; Bernhardt D; Haefner MF; Krauss J; Kargus S; Freudlsperger C; Plinkert P; Flechtenmacher C; Herfarth K; Debus J; Rieken S
Front Oncol; 2019; 9():1420. PubMed ID: 31921675
[No Abstract] [Full Text] [Related]
51. Salivary Duct Carcinoma of the Parotid: Outcomes with a Contemporary Multidisciplinary Treatment Approach.
Mifsud M; Sharma S; Leon M; Padhya T; Otto K; Caudell J
Otolaryngol Head Neck Surg; 2016 Jun; 154(6):1041-6. PubMed ID: 26980918
[TBL] [Abstract][Full Text] [Related]
52. Treatment patterns and outcomes of palliative systemic therapy in patients with salivary duct carcinoma and adenocarcinoma, not otherwise specified.
Sousa LG; Wang K; Torman D; Binks BJ; Rubin ML; Andersen CR; Lewis WE; Rivera MJ; Kaya D; El-Naggar AK; Hanna EY; Esmaeli B; Frank SJ; Bell D; Glisson BS; Rodon J; Meric-Bernstam F; Lee JJ; Ferrarotto R
Cancer; 2022 Feb; 128(3):509-518. PubMed ID: 34661906
[TBL] [Abstract][Full Text] [Related]
53. Incurable advanced salivary gland tumours: a retrospective analysis and peek into the perplexing clinical and molecular intricacies from a tertiary care centre in India.
Sansar B; Singh N; Gupta A; Mishra BK; Sharma A; Rai R; Gupta P; Kapoor A
Ecancermedicalscience; 2023; 17():1602. PubMed ID: 37799960
[TBL] [Abstract][Full Text] [Related]
54. Prognostic value of PSMA, c-MET and E-cadherin in salivary duct carcinoma.
van Boxtel W; Uijen MJM; Verhaegh GW; Willems SM; Jonker MA; ; Schalken JA; van Engen-van Grunsven ICH; van Herpen CML
Oral Oncol; 2020 Nov; 110():105018. PubMed ID: 33039794
[TBL] [Abstract][Full Text] [Related]
55. Alterations associated with androgen receptor gene activation in salivary duct carcinoma of both sexes: potential therapeutic ramifications.
Mitani Y; Rao PH; Maity SN; Lee YC; Ferrarotto R; Post JC; Licitra L; Lippman SM; Kies MS; Weber RS; Caulin C; Lin SH; El-Naggar AK
Clin Cancer Res; 2014 Dec; 20(24):6570-81. PubMed ID: 25316813
[TBL] [Abstract][Full Text] [Related]
56. Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical analysis of 13 cases and review of the literature.
Fan CY; Wang J; Barnes EL
Am J Surg Pathol; 2000 Apr; 24(4):579-86. PubMed ID: 10757407
[TBL] [Abstract][Full Text] [Related]
57. Adjuvant Treatment of the Salivary Duct Carcinoma with Her2 Overexpression.
Berendika J; Jungić S; Tubić B; Malčić Kecman G; Rakita I; Gojković Z; Vještica M; Nikić G; Babić B
Case Rep Oncol; 2021; 14(1):610-615. PubMed ID: 33976642
[TBL] [Abstract][Full Text] [Related]
58. Androgen Deprivation Therapy for Intracranial Metastasis of a Salivary Duct Carcinoma: Case Report.
Rösch M; Bieg C; Savic S; Buess M
Case Rep Oncol; 2023; 16(1):109-115. PubMed ID: 36844935
[TBL] [Abstract][Full Text] [Related]
59. Parotid salivary duct carcinoma: a single institution's 20-year experience.
Stodulski D; Mikaszewski B; Majewska H; Kuczkowski J
Eur Arch Otorhinolaryngol; 2019 Jul; 276(7):2031-2038. PubMed ID: 31062093
[TBL] [Abstract][Full Text] [Related]
60. Clinicopathological and immunohistochemical behavior of ductal carcinoma of the salivary and lacrimal gland in a Mexican Mestizo population.
Luna-Ortiz K; Dominguez-Malagon H; Corredor-Alonso GE; Reynoso-Noveron N; Herrera-Ponzanelli C; Luna-Peteuil Z; Zacarias-Ramon LC
Eur Arch Otorhinolaryngol; 2022 Jan; 279(1):327-333. PubMed ID: 33763743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
